In 2016, the Evidera payer strategy team undertook research to determine the market access implications of surrogate
|
|
- Percival Hall
- 6 years ago
- Views:
Transcription
1 Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser In 2016, the Evidera payer strategy team undertook research to determine the market access implications of surrogate endpoint selection and the optimal approach for their use within clinical development programs. These insights were generated through analysis of case study examples from key therapy areas and primary research with three payers per market in Germany, England, and the U.S. The importance of this research is evident from the fact that almost half of all novel therapies approved by the U.S. Food and Drug Administration (FDA) in the past five years have relied on using surrogate endpoints within pivotal clinical trials for the demonstration of patient benefit. Similar surrogate endpoints have been widely accepted by the European Medicines Agency (EMA) for the regulatory approval of novel therapies. Acceptability of a surrogate endpoint at the regulatory level is not, however, a guarantor of relevance to payers to support pricing and market access decision making. Payers generally require a surrogate endpoint to demonstrate a validated correlation with the final clinical endpoint, with a clear justification for use within a specific therapy area or patient group. Three main payer challenges in the use of surrogate endpoints 1 Perception of surrogate endpoints as a cost-free shortcut by the industry* Manufacturers need to take a longer strategic approach Actual value and limitations must be considered Need for an evidence development strategy understanding the advantages and disadvantages 2 Low correlation of the surrogate endpoint to the final clinical endpoint* Gap between the surrogate endpoint and final clinical endpoint creates uncertainty Better understanding on how to manage the gap is needed 3 Lack of patient relevance and validation* Manufacturers must ensure enough time is allocated start ahead of time * Based on Evidera study with six national payers per market 2015/2016 evidera.com
2 WHEN IS A SURROGATE ENDPOINT ACCEPTABLE FOR PAYERS as a clinically relevant measure of therapeutic benefit? Our research indicates disparity between payers in Germany, England, and the U.S. as to how a surrogate endpoint should be validated, in which indications a surrogate may be justified, and which surrogate endpoints are acceptable measures of clinical value. In clinical trials, a surrogate endpoint (or marker) is a measure of effect of a specific treatment that may correlate with a hard clinical effect but does not necessarily have a guaranteed relationship. Regulatory approval and pricing and reimbursement decisions often need to be based on surrogate endpoints for the following key reasons: 1. Efficacy data based on clinical endpoints require a large sample size and long follow-up This can present a challenge for therapies in chronic diseases and/or having a small expected effect size 2. Treatments are becoming more effective, therefore endpoints are reached later Longer follow-up is needed to observe the outcome Only a small effective size for the clinical outcome when observed early 3. There can be ethical issues in stopping a trial early once the investigational product is proved to be superior based on other outcomes 4. Unbiased clinical endpoints sometimes cannot be observed due to Crossover to the efficacious therapy Emergence of many possible subsequent therapies In principle payers agree that the use of surrogate endpoints is at times unavoidable. Payer consensus that value can only be demonstrated with a surrogate endpoint in particular situations Market Are surrogate endpoints sometimes the only way to demonstrate value? Yes, proxies are sometimes needed when a longer follow-up is required to observe the outcome, due to increasingly effective treatments resulting in endpoints being reached later Yes, with rare conditions when it is not possible to see outcomes in the short-term Yes, specifically in viral diseases such as HCV though even any QoL endpoint is better than laboratory data Rationale Example: OS in cancer where treatments are becoming more effective and so endpoints are reached later, The median OS gets pushed further and further out which is a good thing but how do we determine what the OS is and how do we compare treatment A to treatment B? More pressure to treat people when you have an innovative drug and there is lack of an alternative Must still be linked to the final endpoint, and correlating in a clinically meaningful way Not only the validation is critical but also the rationale for the selected endpoint, e.g., with HCV it cannot be mortality but the need for liver transplant or occurrence of HCC * Based on Evidera study with six national payers per market 2015/ Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser
3 The FDA and EMA will often accept evidence from clinical trials that show a clear benefit on a surrogate marker, subject to an acceptable benefit/risk ratio for patients. Payers, however, consistently seek a surrogate endpoint to be patient-relevant with a strong correlation to a hard clinical endpoint. Across markets, payers have varying opinions as to when a surrogate endpoint is patient-relevant and how validity in terms of correlation with hard clinical outcomes should be demonstrated to support positive health technology assessment (HTA). Payers seek a surrogate endpoint to be patient relevant with a strong correlation to the final clinical endpoint Country specific payer quotations SEs are sometimes an issue. It becomes more an of an issue with expensive medications. For inexpensive medications, it s not as much of a big deal. Traditionally, the biggest emphasis on surrogates I think has been in oncology. The issue is always that there are not enough patients, not enough time to have one of the patient-centered endpoints, usually overall survival and QoL which is usually what patients are usually the most interested Medical director at large health plan I am concerned because I think they have been used previously as a short cut to achieving regulatory approval and market access in situations where clinical data collection is feasible and necessary to understand the full incremental clinical value/detriments vs. current standard of care Former NICE technology appraisal committee member Very concerned. It s about whether the endpoint is patient relevant or not. When something is patient relevant then it could be a surrogate endpoint, we don t mind. But it must be patient relevant. I am concerned about the inappropriate use when the use should be for ethical reasons Head of quality assurance and drug reimbursement for regional KV What payers want to see when using a surrogate endpoint in P&R evaluations Correlation of the surrogate endpoint to a patient-centered outcome, e.g., QoL, functionality, pain reduction Strong emphasis on patients perspective Imperative for NICE decision making and proof of relationship to the QALY: Strong correlation to the final clinical endpoint Patient relevant endpoints Additional evidence of the clinical benefits of the surrogate should be made available Patient relevant and validated Ethically important scenarios which are justifiable and established by several ethical committees The GBA tends to accept SE when there is a clear established relationship to the hard clinical patient relevant endpoint. Can help in the future, and the validation trial can be referred to Head of drugs department in sickness fund Level of confidence using surrogate endpoints in P&R evaluations* Confident Not confident SE: Surrogate endpoints; QoL: Quality of life; QALY: Quality-adjusted life years; * Based on Evidera study with six national payers per market 2015/2016 P&R Pricing and Reimbursement CASE STUDY: IQWIG S OPINION ON THE VALIDITY OF SURROGATE ENDPOINTS IN ONCOLOGY In principle, the use of surrogate endpoints is considered acceptable if validated. However, comprehensive data are required to validate a surrogate endpoint, preferably a meta-analysis of several randomized trials showing sufficient certainty of results. In order to demonstrate validity, a high correlation between effects on the surrogate and the patient-relevant endpoint is usually required (0.9 is considered as a potential threshold). In cases where no high correlation is evident, surrogate threshold effect (STE) can be provided to support the validity if sufficiently large effects on the surrogate have been shown. It is not readily possible to transfer conclusions about the validity of surrogates across different diseases, disease grades, or different interventions. IQWiG s opinion on the validity of surrogate endpoints in colon and breast cancer IQWiG concludes that the validity of tumor response parameters as surrogates for patient-relevant endpoints (overall survival) in colon and breast cancer remains unclear, driven by the low reliability of the validation studies. None of the validation studies examined are believed to consistently fulfill recognized quality criteria, with several concerns, including: Different interventions or indications are often analyzed conjointly Either it is unclear how the data had been compiled, or its compilation proved to be non-systematic Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser 3
4 According to IQWiG s guidance, the validity of surrogate endpoints in oncology has to be assessed at multiple levels where patient relevance is paramount STEP 1 STEP 2 STEP 3 Assess reliability of validation results (high / limited / moderate / low reliability) Assess correlation between surrogates and PRE (high / medium / low correlation) If correlation is only medium, assess the effect on the surrogate vs. STE Reliability is assessed based on the following criteria: Application of a recognized approach described in the scientific literature Conduct of analyses to test the robustness and generalizability of results Systematic compilation of the underlying data for the validation Sufficient restriction of indications or degrees of disease severity Sufficient restriction of the interventions investigated Clear definitions of the endpoints investigated A correlation of 0.9 is perceived as a potential threshold for a high correlation of effects on the surrogate and the patient-relevant endpoint (PRE). In cases where a high correlation is not evident, then the effect on surrogate endpoint vs. surrogate threshold effect (STE) will be examined (if available) Proof of support of benefit: if 95% CI of the effect on the surrogate > STE Indication of effect on PRE: if 80% of the effect on the surrogate > STE Based on the above information (reliability of results, the level of correlation between the surrogate and PRE, and the effect on surrogate if needed), IQWiG will make conclusions on the benefit of the new therapy on PRE from its effect on surrogate endpoint. This conclusion could be proof of effect, indication of effect, hint of effect, or no effect. Source: IQWiG Reports Commission No. A10-05 Validity of surrogate endpoints in oncology (version 1.1), 21 Nov 2011; PRE: Patient-relevant endpoint; STE: Surrogate threshold effect PRACTICAL IMPLICATIONS OF SURROGATE ENDPOINT USE ACROSS MARKETS: THE ONCOLOGY CASE The debated case of Progression Free Survival (PFS) as a surrogate endpoint In the U.S., payers confirm that the consideration of surrogate endpoints is widely accepted to inform formulary access. Payers recognize that PFS is an imperfect surrogate but are willing to accept the endpoint to support perceived value in the absence of mature overall survival (OS) data. On the other side, in Germany, PFS is generally widely challenged as a surrogate for overall survival and not considered patient-relevant. THE LIMITED PAYER ACCEPTANCE OF IMAGING AND TUMOR SIZE AS VALUED SURROGATE ENDPOINTS With regards to imaging and tumor response, payers are even more reluctant. German payers do not consider evidence from imaging and tumor size to constitute evidence that demonstrates patient benefit. England payers also state this type of evidence has low relevance for payer decision making due to poor correlation with clinical outcomes. Imaging and tumor size is valued as supporting data for other more relevant endpoints, for example if there is a PFS benefit and immature OS benefit and we are looking at the overall argument for the likely OS benefit. - Former NICE technology appraisal committee member 4 Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser
5 Low payer acceptability in England and Germany of using imaging as a surrogate outcome for P&R decision making in oncology, though U.S. payers see less of a problem Indication Surrogate endpoint Surrogate for Acceptance in payer assessment Key findings on payer perception Widely accepted to inform formulary access, however payers recognize this is an imperfect surrogate and value additional QoL data to support perceived value in the absence of mature OS data Oncology PFS Survival Recognized as an imperfect surrogate but is acceptable in NICE assessment if modeling with available data supports a likely OS benefit. PFS is also implicitly valued in the QALY through likely sustained duration of higher QoL for patients Widely challenged as a surrogate for overall survival, not considered patient relevant Oncology Imaging tumor response Survival Recognized as an imperfect surrogate with potential high divergence with OS, however if a drug is approved with tumor size as a surrogate, it will have coverage unless there is something better. For example, a lot of plans have stepped Xtandi through Zytiga Low relevance for payer decision making due to poor correlation with clinical outcomes. Only valued as supporting data for other more relevant endpoints, e.g., if there is a PFS benefit and immature OS benefit and we are looking at the overall argument for the likely OS benefit Very low relevance for payers. Only reducing symptoms and tumour size is relevant Key: Acceptability of surrogate endpoints in P&R assessment High Low Medium * Based on Evidera study with six national payers per market 2015/2016 KEYTRUDA WAS ABLE TO ESTABLISH PATIENT BENEFIT BEYOND THE SURROGATE ENDPOINT Keytruda (pembrolizumab, Merck) is indicated for: Advanced melanoma following treatment with ipilimumab, or after treatment with ipilimumab and a BRAF inhibitor in patients with BRAF mutation Metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express PD-L1 and have failed treatment with other chemotherapeutic agents The drug received regulatory approval for both indications in 2015 in the U.S. and the EU. For the pricing and reimbursement processes of the melanoma indication in Germany, France, England, and the U.S., the manufacturer presented clinical effectiveness evidence from two clinical trials: o o KEYNOTE-001 was a combined Phase I and II study KEYNOTE-006 was a randomized, international, multicenter, Phase III trial vs. ipilimumab In KEYNOTE-006, Keytruda was associated with statistically significant increases in both progression-free survival (first interim analysis) and overall survival (second interim analysis), compared with ipilimumab. Keytruda was also associated with statistically significantly higher overall response rates compared with ipilimumab. Tumor response rate by computerized tomography (CT) and magnetic resonance imaging (MRI) has been widely used across clinical trials for new therapies in the treatment of metastatic melanoma as a surrogate for improving survival. While tumor response is not an acceptable endpoint to demonstrate patient benefit, the assessments in the HTA markets Germany, France and England provided positive overall benefit ratings for Keytruda. This was mainly due to the fact that most assessments took primarily into account the interim PFS and OS data and regarded the overall response rate (ORR) data as informative only. This clearly demonstrates the reducing importance of the surrogate endpoint where any hard endpoint data may be available. Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser 5
6 Case Study: Pricing and reimbursement outcomes for Keytruda for the treatment of metastatic melanoma Is tumor response rate an acceptable surrogate endpoint? Is tumor response rate patient relevant? Outcome Cost per month U.S. NICE 1 HAS 4, 5 GBA 2, 3 P&R decision and rationale Yes No No No Yes Coverage restricted by medical policy to prescription label $ (2016, Redbook) Pack size: 50mg 15mL vial Undecided in the case of Keytruda NICE valued the interim PFS and OS data and regarded ORR as informative. Overall accepted for NHS use (2016, BNF) Pack size: 50mg 15mL vial No March 2016: SMR important ASMT IV based decision on interim OS and PFS Confidential price taking account of availability under ATU at the time. Final price TBC status Sept 2016 No Feb 2016: GBA: No evidenced benefit in naïve patients BRAF- V600-mutated and in BRAF-V600-wild-type, a significant incremental benefit. Based decision on interim OS and PFS. 8, (2016, Rote-Liste) Pack size: 50mg 15mL vial ATU Temporary Authorisations for USE Reimbursed by Medicare Covered via medical benefit ORR accepted and seen as patient relevant Reimbursed within NHS NICE accepted due to positive interim PFS and OS Reimbursed 100% ASMR IV Surrogate endpoints position ORR not seen as patient relevant if it is the only patient benefit Keytruda ORR not seen as patient relevant if it is the only patient benefit Reimbursed by Social Security Reimbursed given improved QoL and support from interim OS and PFS ORR not seen as patient relevant if it is the only patient benefit KEY LEARNINGS: HTA s accept submissions with the surrogate endpoint ORR if supported by other patient benefits- in the case of Keytruda interim PFS and OS data supported the patient benefit. KEY LEARNING: Using surrogate endpoints to support pricing and reimbursement (P&R) for a novel drug requires a clear chain of evidence be established demonstrating a justified rationale for the absence of hard clinical endpoint data, and the validated correlation of the surrogate endpoint with hard clinical outcomes. A surrogate endpoint is most likely to be an appropriate/acceptable endpoint for a pivotal clinical trial if the following factors are in place. 1. A clear and transparent rationale as to why it is not feasible to collect hard clinical endpoint data E.g., requirement for a long follow-up that is not feasible within a clinical development program (especially important for innovative drugs where there are few alternatives, therefore there may be more pressure to make the drug available) 2. All criteria for the validity of a surrogate endpoint are met, including: Consistency of the association between the surrogate and clinical endpoint Consistency of the association between surrogate endpoints and patient-important outcomes (e.g., quality of life (QoL), pain reduction, activities of daily living) Evidence from trials in the same drug class that improvement in the surrogate endpoint has consistently led to improvement in the target outcome Evidence from trials in other drug classes that improvement in the surrogate endpoint has consistently led to improvement in patient-important outcomes 6 Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser
7 Using surrogate endpoints in P&R requires that a clear chain of evidence is established demonstrating additional patient benefits on mortality/morbidity endpoints 1 Characteristics of successfully developed and accepted surrogate endpoints across key markets Biological plausibility Prognosis of disease for individual patients Incremental impact on outcomes in clinical trials statistical significance Direct association between the disease mechanism, the surrogate endpoint, and the clinical endpoint Clear demonstration of a change in disease status for individual patients caused by a change in the surrogate endpoint Clear association between a change in surrogate endpoint caused by a therapeutic intervention, and the ultimate clinical outcome within a trial There must be more in the evidence package than just the surrogate endpoint otherwise the value proposition is hard to believe and to assess the value to the patient and its improvement in health Former IQWiG member, Germany REFERENCES 1 U.S. Food and Drug Administration. Novel Drugs Approved Using Surrogate Endpoints. Available at: Testimony/UCM pdf. Accessed November 1, U.S. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry and FDA Staff: Qualification Process for Drug Development Tools. January Available at: ucm pdf. Accessed November 1, Biomarkers Definitions Working Group. Biomarkers and Surrogate Endpoints: Preferred Definitions and Conceptual Framework. Clin Pharmacol Ther Mar;69(3): doi: /mcp Institute for Quality and Efficiency in Health Care (IQWiG) Reports - Commission No. A Validity of Surrogate Endpoints in Oncology. Available at: Accessed November 1, European Medicines Agency. Keytruda (pembrolizumab). Available at: medicines/003820/human_med_ jsp&mid=wc0b01ac058001d124. Accessed November 1, U.S. Food and Drug Administration. Approved Drugs - Pembrolizumab (KEYTRUDA). Available at: ApprovedDrugs/ucm htm. Accessed November 1, National Institute for Health and Care Excellence (NICE). Technology Appraisal Guidance [TA357]. Pembrolizumab for Treating Advanced Melanoma after Disease Progression with Ipilimumab. 07 October Available at: Accessed November 1, Institute for Quality and Efficiency in Health Care (IQWiG). Press Release. Pembrolizumab in Advanced Melanoma: Added Benefit for Certain Patients Available at: Accessed November 1, REFERENCES (CONTINUED ON NEXT PAGE) Payer Expectations of Surrogate Endpoints in Pricing and Reimbursement The Brain Teaser 7
8 REFERENCES (CONTINUED) 9 Gemeinsamer Bundesausschuss. Tragende Gründe. zum Beschluss des Gemeinsamen Bundesausschusses über eine Änderung der Arzneimittel- Richtlinie (AM-RL): Anlage XII - Beschlüsse über die Nutzenbewertung von Arzneimitteln mit neuen Wirkstoffen nach 35a SGB V - Pembrolizumab (Decision of the German Federal Joint Committee on Amending the Medicinal Products Directive (AM-ROL): System XII - Decisions on Medicinal Products Containing New Active Substances According to Section 35a of the SGB V - Pembrolizumab). 4 February Available at: Accessed November 1, Haute Autorité De Santé (HAS). Cancerologie Nouveau Medicament. Synthese D Avis Du College De La HAS. KEYTRUDA (pembrolizumab), anticorps anti-pd1 (Cancer New Drug. Summary of the Opinion of the College of HAS. KEYTRUDA (pembrolizumab), antibody anti-pd1). April Available at: Accessed November 1, Paitraud D. VIDAL - The Online Database of Liberal Prescribers. KEYTRUDA (pembrolizumab): Nouveau Principe Actif Dans L immunothérapie du Mélanome Avancé (KEYTRUDA [pembrolizumab]: Advanced New Active Ingredient in Immunotherapy of Melanoma). 21 October Available at: Accessed November 1, Garde D. Merck Receives Accelerated Approval of KEYTRUDA (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy. FierceBiotech. September 4, Available at: Accessed November 1, U.S. Food and Drug Administration. Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. May Available at: Accessed November 1, U.S EUR +44 (0) info@evidera.com evidera.com
Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531
Pembrolizumab for untreated PD- L1-positive metastatic non-small-cell lung cancer Technology appraisal guidance Published: 18 July 2018 nice.org.uk/guidance/ta531 NICE 2018. All rights reserved. Subject
More informationValue-based frameworks in oncology
28 November 2017 Value-based frameworks in oncology Clarity or confusion? Prepared for: European Statistical Meeting on Latest Trends in HTA Prepared by: Jan McKendrick, Senior Director PRMA Consulting
More informationWHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example
WHY LOOK FOR ADDITIONAL DATA TO ENRICH THE KAPLAN-MEIER CURVES? Immuno-oncology, only an example YIDOU ZHANG Health Economics and Payer Analytics Director Oncology Payer Evidence and Pricing, AstraZeneca
More informationTechnology appraisal guidance Published: 11 January 2017 nice.org.uk/guidance/ta428
Pembrolizumab for treating PD- L1-positive non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 11 January 2017 nice.org.uk/guidance/ta428 NICE 2018. All rights reserved.
More informationOncology HTA: Canada versus UK experiences. Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014
Oncology HTA: Canada versus UK experiences Isabelle Chabot PhD ARCC Conference - Toronto, 12 May 2014 Disclosure I worked on this analysis while a full-time employee at Pfizer. I am now the Principal at
More informationSingle Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV melanoma
Single Technology Appraisal (STA) Nivolumab for adjuvant treatment of resected stage III and IV Response to consultee and commentator comments on the draft remit and draft scope (pre-referral) Comment:
More informationTechnology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab Technology appraisal guidance Published: 7 October 2015 nice.org.uk/guidance/ta357 NICE 2018. All rights reserved.
More informationTechnology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy Technology appraisal guidance Published: 16 May 2018 nice.org.uk/guidance/ta520 NICE 2018. All rights
More informationCost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma.
Cost-effectiveness of nivolumab with ipilimumab (Opdivo with Yervoy ) for the treatment of advanced (unresectable or metastatic) melanoma. The National Centre for Pharmacoeconomics (NCPE) has issued a
More informationMerck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference
Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions
More informationAnalyzing Health Technology Assessment (HTA) Decisions in Oncology
Analyzing Health Technology Assessment (HTA) Decisions in Oncology Funding for this research was provided by PhRMA. Avalere retained full editorial control. Avalere Health An Inovalon Company May 31, 2018
More informationNICE Guidelines for HTA Issues of Controversy
NICE Guidelines for HTA Issues of Controversy Mark Sculpher, PhD Professor of Health Economics University of York, UK LMI, Medicines Agency in Norway and the Norwegian Knowledge Centre for the Health Services:
More informationTechnology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta483
Nivolumab for previously treated squamous non-small-cell lung cancer Technology appraisal guidance Published: 1 November 2017 nice.org.uk/guidance/ta483 NICE 2018. All rights reserved. Subject to Notice
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationEuropean Experience and Perspective on Assessing Value for Oncology Products. Michael Drummond Centre for Health Economics, University of York
European Experience and Perspective on Assessing Value for Oncology Products Michael Drummond Centre for Health Economics, University of York Outline of Presentation The European landscape on access to
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationAccess to newly licensed medicines. Scottish Medicines Consortium
Access to newly licensed medicines Scottish Medicines Consortium Modifiers The Committee has previously been provided with information about why the SMC uses modifiers in its appraisal process and also
More informationOverall survival: 1 st line therapy
1 3 Overall survival: 1 st line therapy 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015 Presented By Veena Shankaran at 2016 ASCO Annual Meeting
More informationBevacizumab for the treatment of recurrent advanced ovarian cancer
Bevacizumab for the treatment of recurrent advanced ovarian cancer ERRATUM This report was commissioned by the NIHR HTA Programme as project number 11/40 Page 2 This document contains errata in respect
More informationApproval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology
Approval of pembrolizumab (MSI- H/dMMR) and considerations for site-agnostic development of drugs in oncology Steven Lemery, MD, MHS Associate Director, DOP2 Traditional development paradigm Based on tumor
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationNational Institute for Health and Care Excellence. Single Technology Appraisal (STA)
National Institute for Health and Care Excellence Single Technology Appraisal (STA) Nivolumab for treating advanced (unresectable or metastatic) melanoma At the scoping consultation stage, the scopes for
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationSeptember 2017 A LOOK AT PARP INHIBITORS FOR OVARIAN CANCER. Drugs Under Review. ICER Evidence Ratings. Other Benefits. Value-Based Price Benchmarks
September 2017 Drugs Under Review ICER s report reviewed the clinical effectiveness and value of olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro),as
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationImmunotherapies in melanoma: regulatory perspective. Jorge Camarero (AEMPS)
Immunotherapies in melanoma: regulatory perspective Jorge Camarero (AEMPS) Challenges for the approval of anti-cancer immunotherapeutic drugs EMA-CDDF joint meeting, London 4-5 February 2016 disclaimers
More informationIbrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL)
Ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma (MCL) Post consultation appraisal committee meeting Dr Jane Adam 2 nd November 2017 Slides for Projector and Public 1 Preliminary
More informationTechnology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487
Venetoclax for treating chronic lymphocytic leukaemia Technology appraisal guidance Published: 8 November 2017 nice.org.uk/guidance/ta487 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationEmpagliflozin/metformin
IQWiG Reports Commission No. A16-13 Empagliflozin/metformin Benefit assessment according to 35a Social Code Book V 1 Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Empagliflozin/Metformin
More informationTechnology appraisal guidance Published: 12 December 2012 nice.org.uk/guidance/ta269
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma Technology appraisal guidance Published: 12 December 2012 nice.org.uk/guidance/ta269 NICE 2018. All
More informationEarly benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view)
Early benefit assessment of new drugs 5-year experiences of AMNOG (from IQWiG s point of view) Stefan Lange, MD, PhD Deputy director Institute for Quality and Efficiency in Health Care (IQWiG) Skipka G,
More informationfor patients with ECOG PS 0-1 as indicated in the CheckMate-067 trial. Upon reconsideration of the Initial Recommendation, perc noted PAG s feedback requesting guidance on extrapolating eligibility to
More informationTechnology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta319
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma Technology appraisal guidance Published: 23 July 2014 nice.org.uk/guidance/ta319 NICE 2018. All rights reserved. Subject
More informationTechnology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516
Cabozantinib for treating medullary thyroid cancer Technology appraisal guidance Published: 28 March 2018 nice.org.uk/guidance/ta516 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTechnology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476
Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer Technology appraisal guidance Published: 6 September 2017 nice.org.uk/guidance/ta476 NICE 2018. All
More informationPTAC meeting held on 5 & 6 May (minutes for web publishing)
PTAC meeting held on 5 & 6 May 2016 (minutes for web publishing) PTAC minutes are published in accordance with the Terms of Reference for the Pharmacology and Therapeutics Advisory Committee (PTAC) and
More informationManaged Access Agreement. Osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer
Managed Access Agreement Osimertinib for treating metastatic EGFR and T790M mutation-positive non-small-cell lung cancer Cancer Drugs Fund Data Collection Arrangement Osimertinib for locally advanced or
More informationAccess to clinical trial information and the stockpiling of Tamiflu. Department of Health
MEMORANDUM FOR THE COMMITTEE OF PUBLIC ACCOUNTS HC 125 SESSION 2013-14 21 MAY 2013 Department of Health Access to clinical trial information and the stockpiling of Tamiflu 4 Summary Access to clinical
More informationTechnology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416
Osimertinib for treating locally advanced or metastatic EGFR T790M mutation- positive non-small-cell lung cancer Technology appraisal guidance Published: 26 October 2016 nice.org.uk/guidance/ta416 NICE
More informationTechnology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472
Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab Technology appraisal guidance Published: 30 August 2017 nice.org.uk/guidance/ta472 NICE 2018. All rights reserved.
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationCancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives
BBS PSI Scientific Meeting: Empower the immune system to fight cancer Cancer Immunotherapy from the Health Technology Assessment (HTA) and Payer Perspectives Fred Sorenson, Xcenda Disclaimer and Acknowledgements
More informationSecretary-General of the European Commission, signed by Mr Jordi AYET PUIGARNAU, Director
COUNCIL OF THE EUROPEAN UNION Brussels, 13 February 2014 (OR. en) 6438/14 COVER NOTE From: date of receipt: 3 February 2014 To: No. Cion doc.: PHARM 14 SAN 72 MI 161 COMPET 107 DELACT 29 Secretary-General
More informationTechnology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500
Ceritinib for untreated ALK-positive non- small-cell lung cancer Technology appraisal guidance Published: 24 January 2018 nice.org.uk/guidance/ta500 NICE 2018. All rights reserved. Subject to Notice of
More informationThe cost of cancer treatment
The cost of cancer treatment Lieven Annemans Ghent University Lieven.annemans@ugent.be January 2016 What s the problem? those prices are too high the budgets will explode these drugs offer survival benefit
More informationTechnology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489
Vismodegib for treating basal cell carcinoma Technology appraisal guidance Published: 22 November 2017 nice.org.uk/guidance/ta489 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTechnology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta422
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer Technology appraisal guidance Published: 21 December 2016 nice.org.uk/guidance/ta422 NICE 2018.
More informationpcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION
pcodr EXPERT REVIEW COMMITTEE (perc) INITIAL RECOMMENDATION The CADTH pan-canadian Oncology Drug Review (pcodr) was established by Canada s provincial and territorial M inistries of Health (with the exception
More informationDabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Dabrafenib for treating unresectable or metastatic BRAF V600 Issued: October 2014 guidance.nice.org.uk/ta321 NICE has accredited the process used by the Centre for Health Technology Evaluation at NICE
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer Technology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta411 NICE 2017. All rights reserved.
More informationNivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1
For public no AIC or CIC Nivolumab for adjuvant treatment of resected stage III and IV melanoma [ID1316] STA Lead team presentation: Cost Effectiveness Part 1 1st Appraisal Committee meeting Committee
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL. Health systems and products Medicinal products authorisations, EMA
Ref. Ares(2012)1405774-28/11/2012 EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Health systems and products Medicinal products authorisations, EMA DELEGATED ACT ON POST-AUTHORISATION EFFICACY
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta440 NICE 2017. All rights reserved. Subject
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationConcepts and Case Study Template for Surrogate Endpoints Workshop. Lisa M. McShane, Ph.D. Biometric Research Program National Cancer Institute
Concepts and Case Study Template for Surrogate Endpoints Workshop Lisa M. McShane, Ph.D. Biometric Research Program National Cancer Institute Medical Product Development GOAL is to improve how an individual
More informationTechnology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183
Topotecan for the treatment of recurrent and stage IVB cervical cancer Technology appraisal guidance Published: 28 October 2009 nice.org.uk/guidance/ta183 NICE 2018. All rights reserved. Subject to Notice
More informationWhat do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden
What do we mean by brand value (innovation) within the pharmaceutical sector? Biomedicine Master Program, Lund University, Sweden Sunil Ramkali Account Director, W Communication Agency 11 th November 2014
More informationTechnology appraisal guidance Published: 7 March 2018 nice.org.uk/guidance/ta509
Pertuzumab with trastuzumab and docetaxel el for treating HER2-positive breast cancer Technology appraisal guidance Published: 7 March 20 nice.org.uk/guidance/ta509 NICE 20. All rights reserved. Subject
More informationName: Ben Cottam Job title: Policy and Communications Officer
Name: Ben Cottam Job title: Policy and Communications Officer Organisation/Institution: Faculty of Pharmaceutical Medicine Is this input submitted as an organisational or individual response? Organisational
More informationBuilding a Premier Oncology Biotech
Building a Premier Oncology Biotech August 208 Forward-Looking Statements All of the statements in this presentation that are not statements of historical facts constitute forward-looking statements within
More informationLights and sheds of early approval of new drugs in clinical routine. Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy
Lights and sheds of early approval of new drugs in clinical routine Carmen Criscitiello, MD, PhD European Institute of Oncology Milan, Italy RCT 5-10% pts «real» patients are here Clin. Pharm. Ther. 2012
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationAdjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial
Adjusting the Crossover Effect in Overall Survival Analysis Using a Rank Preserving Structural Failure Time Model: The Case of Sunitinib GIST Trial Xin Huang 1 and Qiang (Casey) Xu 2 1 Pfizer Oncology
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) June 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More informationFirst Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor
September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented
More informationThe Roles of Short Term Endpoints in. Clinical Trial Planning and Design
The Roles of Short Term Endpoints in Clinical Trial Planning and Design Christopher Jennison Department of Mathematical Sciences, University of Bath, UK http://people.bath.ac.uk/mascj Roche, Welwyn Garden
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492
Atezolizumab for untreated PD- L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta492
More informationUrgent Clinical Commissioning Policy Statement: Alemtuzumab for treating relapsingremitting. sclerosis third cycle (all ages)
Urgent Clinical Commissioning Policy Statement: Alemtuzumab for treating relapsingremitting multiple sclerosis third cycle (all ages) NHS England Reference: 170075P 1 Equality statement Promoting equality
More informationstatus should be eligible for treatment with atezolizumab. perc acknowledged the small number of patients with an EGFR or ALK mutation positive disease recruited on the trials but agreed that the overall
More informationTechnology appraisal guidance Published: 20 December 2017 nice.org.uk/guidance/ta496
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor- positive, HER2-negative, e, locally advanced or metastatic breast cancer Technology appraisal guidance Published: 20 December
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationvemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd.
Resubmission vemurafenib 240mg film-coated tablet (Zelboraf ) SMC No. (792/12) Roche Products Ltd. 08 November 2013 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationTechnology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta405
Trifluridine tipirracil for previously treated metastatic colorectal cancer Technology appraisal guidance Published: 24 August 2016 nice.org.uk/guidance/ta405 NICE 2018. All rights reserved. Subject to
More informationInvolvement of people affected
Involvement of people affected in the dossier assessment 1 1 Translation of the document Beteiligung von Betroffenen bei der Dossierbewertung (Version 1.1; Status: 28 July 2017). Please note: This translation
More informationGuideline on the use of minimal residual disease as a clinical endpoint in multiple myeloma studies
1 2 3 26 July 2018 EMA/CHMP/459559/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on the use of minimal residual disease as a clinical endpoint in multiple Draft Draft agreed
More informationExecutive Summary. Positron emission tomography (PET and PET/CT) in malignant lymphoma 1. IQWiG Reports Commission No. D06-01A
IQWiG Reports Commission No. D06-01A Positron emission tomography (PET and PET/CT) in malignant lymphoma 1 Executive Summary 1 Translation of the executive summary of the final report Positronenemissionstomographie
More information(Regulatory) views on Biomarker defined Subgroups
(Regulatory) views on Biomarker defined Subgroups Norbert Benda Disclaimer: Views expressed in this presentation are the author's personal views and not necessarily the views of BfArM Biomarker defined
More informationGreg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia
NICE PBAC PBS CADTH Access Challenges Greg Cook Associate Director, Market Access, Bristol-Myers Squibb Australia Disclaimer: The views expressed in this presenta5on are those of the author not his employer
More informationTechnology appraisal guidance Published: 11 April 2018 nice.org.uk/guidance/ta517
Avelumab for treating metastatic Merkelel cell carcinoma Technology appraisal guidance Published: 11 April 2018 nice.org.uk/guidance/ta517 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationTechnology appraisal guidance Published: 7 February 2018 nice.org.uk/guidance/ta505
Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma Technology appraisal guidance Published: 7 February 2018 nice.org.uk/guidance/ta505 NICE 2018. All rights
More informationPATIENTS REPORTED OUTCOMES IN ONCOLOGY PATIENT- CENTERED DRUG DEVELOPMENT: OPPORTUNITIES & CHALLENGES
PATIENTS REPORTED OUTCOMES IN ONCOLOGY PATIENT- CENTERED DRUG DEVELOPMENT: OPPORTUNITIES & CHALLENGES 10th Alpine Conference Innsbruck, Austria, 27 February 2018 1 Disclaimer The views and opinions expressed
More informationCytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer
November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.
More informationTechnology appraisal guidance Published: 31 August 2017 nice.org.uk/guidance/ta473
Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck Technology appraisal guidance Published: 31 August 2017 nice.org.uk/guidance/ta473 NICE 2018. All rights reserved.
More informationMATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS
MATCHMAKING IN ONCOLOGY CHALLENGES AND COMBINATION STRATEGY FOR NOVEL TARGETED AGENTS DR. RACHEL E. LAING*, OLIVIER LESUEUR*, STAN HOPKINS AND DR. SEAN X. HU MAY 2012 Recent advances in oncology, such
More informationStatistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials
Statistical, clinical and ethical considerations when minimizing confounding for overall survival in cancer immunotherapy trials Dominik Heinzmann, PhD Global Development Team Leader HER2 Associate Director
More informationpatients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease
patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease First, perc agreed with CGP that the diagnosis of urothelial
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationSubgroup Mixable Inference for Targeted Therapies
Subgroup Mixable Inference for Targeted Therapies Jason C. Hsu The Ohio State University Duke Industry Statistics Symposium September 2017 In collaboration with Hong Tian, Haiyan Xu, Hui-Min Lin, Ying
More informationRegulatory Considerations in Oncology Trials in China. Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi
Regulatory Considerations in Oncology Trials in China Jiang, Frank, MD, PhD VP, Asia Pacific R&D, Sanofi 1 Disclaimer The views and opinions provided are those of the speaker and do not reflect those of
More informationDelcath Investor Presentation (OTCQB: DCTH)
Delcath Investor Presentation (OTCQB: DCTH) March 2018 1 DELCATH SYSTEMS, INC Forward-looking Statements This presentation contains forward-looking statements, within the meaning of the federal securities
More informationPriority setting at a national level NICE - England. Gillian Leng Deputy Chief Executive, NICE September 2016
Priority setting at a national level NICE - England Gillian Leng Deputy Chief Executive, NICE September 2016 Areas to cover The role of NICE in the UK health system General approach to appraising new drugs
More informationTechnology appraisal guidance Published: 22 October 2014 nice.org.uk/guidance/ta321
Dabrafenib afenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma Technology appraisal guidance Published: 22 October 2014 nice.org.uk/guidance/ta321 NICE 2018. All rights
More informationCancer Drugs Fund. Managed Access Agreement. Nivolumab for previously treated nonsquamous non-small-cell lung cancer
Cancer Drugs Fund Managed Access Agreement Nivolumab for previously treated nonsquamous non-small-cell lung cancer NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data Collection Arrangement
More information1 st Appraisal Committee meeting Background & Clinical Effectiveness Gillian Ells & Malcolm Oswald 24/11/2016
Lead team presentation Nivolumab for treating recurrent or metastatic squamous-cell carcinoma of the head and neck after platinum-based chemotherapy [ID971] 1 st Appraisal Committee meeting Background
More informationLead team presentation:
Lead team presentation: Nivolumab for previously treated locally advanced or metastatic nonsquamous non-small-cell lung cancer 1 st Appraisal Committee meeting Background & Clinical Effectiveness Iain
More informationCost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma
Cost-effectiveness of Obinutuzumab (Gazyvaro ) for the First Line Treatment of Follicular Lymphoma The NCPE has issued a recommendation regarding the cost-effectiveness of obinutuzumab (Gazyvaro ). Following
More informationRegulatory and Labeling Challenges with Developing Immuno-Oncology Combination Therapies
Regulatory and Labeling Challenges with Developing Immuno-Oncology Combination Therapies Amy McKee, M.D. Acting Deputy Director, OCE, FDA Supervisory Associate Director, OHOP, CDER, FDA July 16, 2018 Background
More informationCost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy
Cost-effectiveness of ixazomib (Ninlaro ) for the Treatment of Adult Patients with Multiple Myeloma who have Received at Least One Prior Therapy The NCPE has issued a recommendation regarding the cost-effectiveness
More informationPemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer
DOI: 10.3310/hta14suppl2/05 Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer J Greenhalgh,* C McLeod, A Bagust, A Boland, N Fleeman, Y Dundar, J Oyee,
More information